Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.65 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.65 |
| ▸ | BRD4 | O60885 | 3/20 | 0.65 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.65 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.65 |
| ▸ | TNF | P01375 | 1/20 | 0.65 |
| ▸ | IL1B | P01584 | 1/20 | 0.65 |
| ▸ | MAP1LC3B | Q9GZQ8 | 5/20 | 0.59 |
| ▸ | STAT3 | P40763 | 1/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.53 |
| ▸ | AXL | P30530 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31554721 | 0.99 | CRBN (0.64) | CRBNIKZF3BRD4DDB1IKZF1 | |
| SCHEMBL21596986 | 0.94 | CRBN (0.63) | CRBNIKZF3BRD4DDB1IKZF1 | |
| SCHEMBL30438018 | 0.94 | CRBN (0.63) | CRBNIKZF3BRD4DDB1IKZF1 | |
| SCHEMBL30438142 | 0.93 | CRBN (0.62) | CRBNIKZF3BRD4DDB1IKZF1 | |
| SCHEMBL19436877 | 0.93 | CRBN (0.62) | CRBNIKZF3BRD4DDB1IKZF1 | |
| SCHEMBL22636509 | 0.92 | CRBN (0.61) | CRBNIKZF3BRD4DDB1IKZF1 | |
| SCHEMBL21814682 | 0.92 | CRBN (0.61) | CRBNIKZF3BRD4DDB1IKZF1 | |
| SCHEMBL24142000 | 0.92 | CRBN (0.61) | CRBNIKZF3BRD4DDB1IKZF1 | |
| SCHEMBL19747349 | 0.92 | CRBN (0.61) | CRBNIKZF3BRD4DDB1IKZF1 | |
| Hydrochloric Acid SCHEMBL30772822 | 0.92 | CRBN (0.61) | CRBNIKZF3BRD4DDB1IKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110615779-B | Process for preparing lenalidomide derivatives | 上海科技大学 | 2023-03-24 | — | — | CN | claimed |
| US-12630547-B2 | RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | BIOTHERYX, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4731611-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-29 | — | — | EP | disclosed |
| CN-115335373-B | Compounds and uses thereof | 福宏治疗公司 | 2025-05-20 | — | — | CN | disclosed |
| WO-2025101912-A1 | HELLS HELICASE DEGRADERS AND USES THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-05-15 | — | — | WO | disclosed |
| WO-2024263781-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-12-26 | — | — | WO | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230002371-A1 | RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX INC (US) | 2023-01-05 | — | — | US | disclosed |
| EP-4097096-A2 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-115335373-A | Compound and use thereof | 福宏治疗公司 | 2022-11-11 | — | — | CN | disclosed |
| WO-2021155321-A2 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021155321-A2 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021051034-A1 | RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630547-B2 | RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | KRAS, RSU1, NRAS | CRBN 245/4885IKZF3 2390/4885BRD4 3113/4885 |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | CRBN 163/4885IKZF3 1199/4885BRD4 126/4885 |
| US-20230002371-A1 | RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | KRAS, RSU1, RAB1A | CRBN 407/4885IKZF3 2315/4885BRD4 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.